Advancing Childhood Cancer Therapies | ACCT - Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Home > Innovative Approaches > Clinical Trials for Relapsed Cancer (ACCT Clinic)

Share
PrintPrint

Clinical Trials for Relapsed Cancer
Advancing Childhood Cancer Therapies (ACCT) Clinic

For patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option. Phase I and phase II clinical trials provide access to the newest, most innovative therapies to patients.

The Advancing Childhood Cancer Therapies (ACCT) Clinic is dedicated to offering state-of-the-art therapies, advancing the science of pediatric research, and providing personalized care to you and your family. The Clinic includes experts in each type of cancer as well as teams of subspecialists and nurses who are leaders in their respective fields. In August 2016, we joined the Children’s Oncology Group Phase 1 Consortium, one of only 21 such centers in the United States and the only one in New England.

Our currently active phase I and phase II trials for patients with relapsed, recurrent, or refractory cancer are listed below by disease – or search all of our available clinical trials.

If you have questions about which trial might be right for your child or patient, please email us at clinicaltrials@danafarberbostonchildrens.org or call us at 1-855-320-2090. We can help you navigate your options.

Phase I and II Trials for Relapsed and Refractory Cancer

Brain Tumor Trials

A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase I Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Principal Investigator Steven DuBois, MD

A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD

A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD

PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant Brain Tumors
Principal Investigator Susan Chi, MD

A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Principal Investigator Steven DuBois, MD

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD

Phase I-II Study of MEK162 for Children Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Principal Investigator Mark Kieran, MD

Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations>
Principal Investigator Mark Kieran, MD

Open-label, Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment with Surgery or Radiation
Principal Investigator Nicole Ullrich, MD

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors
Principal Investigator Mark Kieran, MD

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Glioma in Children
Principal Investigator Susan Chi, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Leukemia Trials

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD

T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
Principal Investigator Andrew Place, MD

Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
Principal Investigator Steven DuBois, MD

A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Principal Investigator Lewis Silverman, MD

A Phase I Trial of Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell ALL
Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Lymphoma Trials

A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD

Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD

Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD

A Phase I Trial of Temsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Neuroblastoma Trials

A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD

A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD

A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD, MS

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD

A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Principal Investigator Steven DuBois, MD

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD

Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD

A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD

Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD

A Phase I Study of Sorafenib and Cyclophosphamide and Topotecan in Patients with Relapsed and Refractory Neuroblastoma
Principal Investigator Suzanne Shusterman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Kidney, Liver, and Other Solid Tumor Trials

A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD

A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD

Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
Principal Investigator Steven DuBois, MD

A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD

A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Principal Investigator Steven DuBois, MD

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD

Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD

A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD

Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD

Phase I Study of Olaparib with Irinotecan and/or Temezolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior Chemotherapy
Principal Investigator Steven DuBois, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Bone Tumor and Other Sarcoma Trials

A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD

A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD

Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
Principal Investigator Steven DuBois, MD

A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS

Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD

A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
Principal Investigator Steven DuBois, MD

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Principal Investigator Steven DuBois, MD

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD

A Phase 1 Study of Selinexor, a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD

A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD

A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
Principal Investigator Gregory Cote, MD

A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapse or Refractory INI1-Negative Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD

Phase I Study of Olaparib with Irinotecan and/or Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Principal Investigator Steven DuBois, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Stem Cell Transplant and Cellular Therapies

A Phase I Trial of Autologous T-Lymphocytes (CAR T-Cell) Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
Principal Investigator Lewis Silverman

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

Know Your Options
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.
Email Us About Clinical Trials
Top Ranked for Cancer Care
World class cancer care at the #1 Children's Hospital

Learn More
Clinical Trial FAQs
Get answers to common questions about clinical trials: What are clinical trials? Is a clinical trial the right choice for my child?
Participating in Clinical Trials
Precision Cancer Medicine

Precision cancer medicine provides individualized treatment tailored to the specific genetic characteristics of a patient's cancer. Our research and clinical trials are leading the way in precision medicine for pediatric cancer.

Precision Cancer Medicine

Clinical Trials for Relapsed Cancer

Advancing Childhood Cancer Therapies (ACCT) Clinic

Phase I and II Trials for Relapsed and Refractory Cancer

Brain Tumor Trials

Leukemia Trials

Lymphoma Trials

Neuroblastoma Trials

Kidney, Liver, and Other Solid Tumor Trials

Bone Tumor and Other Sarcoma Trials

Stem Cell Transplant and Cellular Therapies

Know Your Options

Top Ranked for Cancer Care

Clinical Trial FAQs

Precision Cancer Medicine